TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03875690
Drug: Injection of methylprednisolone
Normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
Study: NCT00604864
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03442218
Drug: Clorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
Study: NCT00246701
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin
Study: NCT00246701
Drug: Simvastatin + Lovaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin + Lovaza (omega-3-acid ethyl esters)
Study: NCT00279773
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01862640
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, tablets
Study: NCT01384422
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01854437
Drug: Mg Oxide
Normalized name: citric acid/Mg oxide/Na picosulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg orally for 4 weeks
Study: NCT02391181
Drug: Iron Sucrose Azad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study: NCT03936829
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
Study: NCT01101165
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 40-mg tablet x 1 dose taken without food
Study: NCT01101165
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
Study: NCT02391181
Drug: Venofer®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study: NCT00372970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline injection into pylorus.
Study: NCT00601640
Drug: Diclofenac Na gel
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given topically twice daily on days 1-90
Study: NCT02720692
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00508885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00462189
Drug: Immunotoxin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02544282
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Pecs II block
Study: NCT02544282
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General Anesthesia
Study: NCT04607525
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D.
Study: NCT00258791
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00852228
Drug: HAI chronomodulated chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks.
Study: NCT00852228
Drug: HAI conventional chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks.
Study: NCT00335556
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00335556
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03321734
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
Study: NCT03321734
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
Study: NCT04609059
Drug: M201-A Injection
Normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Study: NCT04609059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Study: NCT00331214
Drug: Testosterone Transdermal System
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone patch (300 mcg/day), patch changed twice a week for six months
Study: NCT00331214
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch replaced every 3-4 days for 6 months
Study: NCT02757404
Drug: Manual needle placement injection of Meditoxin®.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
Study: NCT00916006
Drug: PEP005 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015%, three day treatment
Study: NCT00916006
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel, three day treatment
Study: NCT02005666
Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study: NCT02005666
Drug: DUAC® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study: NCT00791089
Drug: LOVAZA Omega 3-acid ethyl esters
Normalized name: omega-3 acid ethyl esters (USP) 1000 MG [Lovaza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
Study: NCT03986528
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
Study: NCT00668811
Drug: SU011248, Sutent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
Study: NCT00244101
Drug: PS Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
Study: NCT00244101
Drug: ISX Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Study: NCT01605136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo subcutaneous implant every 2 months for 6 months
Study: NCT01750957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily, 12 weeks
Study: NCT01750957
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A orally daily, 12 weeks
Study: NCT01750957
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B orally daily, 12 weeks
Study: NCT01366196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
Study: NCT03023059
Drug: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Normalized name: Carbidopa-Levodopa, 25 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT03056339
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 by vein on Days -5 to -3.
Study: NCT03056339
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
Study: NCT00650403
Drug: Paxil® 40 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fed
Study: NCT01272635
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
Study: NCT01272635
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Study: NCT01272635
Drug: Placebo Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Study: NCT00891228
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Study: NCT00891228
Drug: Nestorone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
Study: NCT00891228
Drug: Nestorone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
Study: NCT00891228
Drug: Nestorone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
Study: NCT02967510
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02967510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01848119
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01957202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study: NCT01279616
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg on day +3
Study: NCT00124956
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03761784
Drug: S6G5T-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream
Study: NCT03761784
Drug: S6G5T-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream
Study: NCT01772719
Drug: Simvastatin and zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
Study: NCT00307125
Drug: Placebo plus immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific.
Study: NCT00029523
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01032850
Drug: Sorafenib & Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Study: NCT02652234
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01633814
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal estradiol, delivery rate 100 µg day-1
Study: NCT01633814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch.
Study: NCT01520896
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg
Study: NCT02211144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01952288
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg/day for 12 months
Study: NCT01952288
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT01001572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule or tablet taken orally once daily
Study: NCT02083666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product
Study: NCT01765179
Drug: Oral testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
Study: NCT02997371
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administration as initially intravenous injection followed by a intravenous infusion
Study: NCT00419783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03267940
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 will be administered as per the schedule specified in the respective arms.
Study: NCT03267940
Drug: CIS
Normalized name: Pacis
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS will be administered as per the schedule specified in the respective arms.
Study: NCT04526197
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
Study: NCT00621387
Drug: ofloxacin and roxithromycin
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
Study: NCT02441062
Drug: 68Ga-DOTATOC PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Study: NCT03631563
Drug: Immunosuppressive Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-Fresenius versus ATG
Study: NCT00135967
Drug: mycophenolate mofetil orally 1000 mg twice a day (BID)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00135967
Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00541723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
Study: NCT02905760
Drug: Placebo filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
Study: NCT02905760
Drug: Vascular filling
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
Study: NCT01216384
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive according to the dose group matching number of placebo tablets
Study: NCT00713726
Drug: FentanyL
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
Study: NCT04328636
Drug: Nebulized Magnesium Sulfate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
Study: NCT04328636
Drug: Intravenous Magnesium Sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
Study: NCT00914160
Drug: Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes